Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fenghai Duan

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Plos One|May 15, 2018
Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening TrialTobias Peikert, Fenghai Duan, Srinivasan Rajagopalan, et al.
Contemporary Clinical Trials|March 27, 2025
Effectiveness of out-of-pocket cost COMmunication and financial navigation (CostCOM) in cancer patients: Study protocol for ECOG-ACRIN EAQ222CDGelareh Sadigh, Fenghai Duan, Ilana F Gareen, et al.
European Radiology|January 5, 2017
Interval lung cancer after a negative CT screening examination: CT findings and outcomes in National Lung Screening Trial participantsDavid S Gierada, Paul F Pinsky, Fenghai Duan, et al.
Radiology|March 12, 2015
Association of Coronary Artery Calcification and Mortality in the National Lung Screening Trial: A Comparison of Three Scoring MethodsCaroline Chiles, Fenghai Duan, Gregory W Gladish, et al.
Cancer|September 16, 2004
African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristicsBeth A Jones, Stanislav V Kasl, Christine L Howe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 10, 2017
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trialAli Salavati, Fenghai Duan, Bradley S Snyder, et al.
American Journal of Respiratory and Critical Care Medicine|June 9, 2015
Noninvasive Computed Tomography-based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening TrialFabien Maldonado, Fenghai Duan, Sushravya M Raghunath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology GroupJennifer L Reichek, Fenghai Duan, Lynette M Smith, et al.
Journal of the National Cancer Institute|February 18, 2015
Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235Nitin Ohri, Fenghai Duan, Mitchell Machtay, et al.
Journal of the National Cancer Institute. Monographs|February 24, 2025
Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trialsHanna Bandos, Pedro A Torres-Saavedra, Eva Culakova, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Plos One|May 15, 2018
Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening TrialTobias Peikert, Fenghai Duan, Srinivasan Rajagopalan, et al.
Contemporary Clinical Trials|March 27, 2025
Effectiveness of out-of-pocket cost COMmunication and financial navigation (CostCOM) in cancer patients: Study protocol for ECOG-ACRIN EAQ222CDGelareh Sadigh, Fenghai Duan, Ilana F Gareen, et al.
European Radiology|January 5, 2017
Interval lung cancer after a negative CT screening examination: CT findings and outcomes in National Lung Screening Trial participantsDavid S Gierada, Paul F Pinsky, Fenghai Duan, et al.
Radiology|March 12, 2015
Association of Coronary Artery Calcification and Mortality in the National Lung Screening Trial: A Comparison of Three Scoring MethodsCaroline Chiles, Fenghai Duan, Gregory W Gladish, et al.
Cancer|September 16, 2004
African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristicsBeth A Jones, Stanislav V Kasl, Christine L Howe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 10, 2017
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trialAli Salavati, Fenghai Duan, Bradley S Snyder, et al.
American Journal of Respiratory and Critical Care Medicine|June 9, 2015
Noninvasive Computed Tomography-based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening TrialFabien Maldonado, Fenghai Duan, Sushravya M Raghunath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology GroupJennifer L Reichek, Fenghai Duan, Lynette M Smith, et al.
Journal of the National Cancer Institute|February 18, 2015
Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235Nitin Ohri, Fenghai Duan, Mitchell Machtay, et al.
Journal of the National Cancer Institute. Monographs|February 24, 2025
Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trialsHanna Bandos, Pedro A Torres-Saavedra, Eva Culakova, et al.
Pageof 8